Clinical trial Recruiting at 1 site Interventional Ages 18 to 55

Low-level red light to slow retinal thinning in pathologic myopia

Official title: A Randomized Controlled Trial of LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia

Run by Shanghai Eye Disease Prevention and Treatment Center · NCT07312214 · Data updated 2026-11-12

This trial will test whether twice-daily low-level red light therapy can slow retinal atrophy in adults with pathologic myopia and is safe to use.

Quick facts

Study typeInterventional
Ages18 Years to 55 Years
SexAll
Enrollment158 (estimated)
SponsorShanghai Eye Disease Prevention and Treatment Center
Academic / other
Locations1 site (Shanghai)
StatusRecruiting
StartedDecember 31, 2025
Main results expectedDecember 30, 2028
Study endsDecember 30, 2028
Registry record updatedMay 15, 2026
Trial IDNCT07312214 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–55 with high myopia (spherical equivalent ≤ −6.00 D and axial length ≥ 26.0 mm) and signs of pathologic myopia on fundus exam (META-PM categories 2–4, or category 1 with macular schisis, or reduced central vision meeting the trial criteria) are ideal candidates.

Probably not a fit

People with active myopic choroidal neovascularization requiring anti-VEGF, other retinal diseases (macular hole, diabetic retinopathy, retinal detachment, retinal vein occlusion), very advanced vision loss, or those outside the age/axial length criteria are unlikely to benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial will assign adults with pathologic myopia to either active repeated low-level red light (RLRL) therapy or a visually identical sham device that delivers <10% of the energy. Participants will use the device at home twice daily for 3 minutes per session, five days per week, over 12 months, with clinic visits and tests every three months and symptom diaries kept between visits. Primary interests are whether RLRL modulates choroidal microcirculation and retards progression of retinal atrophy, and whether the therapy is well tolerated over long-term use. The sham control and standardized treatment schedule are intended to separate true biological effects from placebo and routine-care influences.

Why it matters

Potential benefit: If effective, RLRL could slow retinal atrophy progression in pathologic myopia and help preserve vision by improving choroidal microcirculation.

How similar studies have gone: Prior RLRL trials, mainly in children, have shown signals for slowing axial elongation and increasing choroidal thickness, but applying RLRL to slow retinal atrophy in adults with pathologic myopia is largely untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age range: 18 to 55 years old;
* Baseline visual acuity: Best Corrected Visual Acuity (BCVA) ≥ 0.1 (LogMAR ≤ 1.0);
* Meeting the diagnostic criteria for high myopia: Spherical Equivalent (SE) ≤ -6.00 D and Axial Length (AL) ≥ 26.0 mm;
* Meeting one of the following pathological fundus changes:

  (i) Fundus manifestations corresponding to Category 2 (diffuse chorioretinal atrophy), Category 3 (patchy chorioretinal atrophy), or Category 4 (macular atrophy associated with choroidal neovascularization) of the META-PM classification criteria\*; (ii) Category 1 of the META-PM classification criteria\* complicated with macular schisis; (iii) BCVA \< 0.6;

Exclusion Criteria:

* Concurrent with other ophthalmic diseases that may affect visual acuity or outcome assessment, including active myopic choroidal neovascularization (CNV) requiring anti-VEGF therapy, macular hole, vitreous hemorrhage, diabetic retinopathy, retinal detachment, retinal vein occlusion, optic neuritis, uveitis, severe cataract, and glaucoma;
* Systemic contraindications: Photosensitive epilepsy, autoimmune diseases (e.g., systemic lupus erythematosus), or pregnant/lactating women; Patients who have undergone intraocular surgery, laser treatment, or ophthalmic medication therapy within 3 months prior to enrollment;
* Patients unable to comply with regular follow-up (e.g., due to remote residence) or with cognitive impairment;
* Opaque refractive media that hinder fundus examination.

Where it's running

  • Shanghai Eye Disease Prevention and Treatment Center
    Shanghai, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.